GeneCure has developed a patented platform technology of gene transfer based on a primate lentivirus. This novel gene transfer technology has the ability to efficiently transfer genes into primary human cells without causing harm to humans. This technology will be employed for developing gene-based therapeutics for human diseases including both inherited and infectious diseases. Current research and development is focused on using this technology to develop human vaccines against HIV, Hepatitis C, Hepatitis B, and SARS. The firm is focused on using its novel gene transfer technology to develop treatments for life-threatening human diseases, including genetic diseases, infectious diseases, and cancers. GeneCure has developed a technology to effectively deliver genes into human cells, and this technology will be employed to deliver therapeutic genes into humans as treatment and / or prevention. GeneCure's platform technology for gene transfer is based on a primate lentivirus, which has the ability to efficiently transfer genes into primary human cells yet cause no harm in humans-----the major hurdle for current gene therapy protocols. One of applications for GeneCure's platform technology is to develop novel vaccine approaches for several infectious diseases and cancers. GeneCure's lead product is a therapeutic HIV-1 vaccine for HIV-1 positive patients. GeneCure's business strategy is to enter corporate partnership with pharmaceutical companies to commercialize gene-based therapeutics developed based on its proprietary technology. WhileGeneCure will conduct early research and pre-clinical studies, GeneCure's partners will be responsible for conducting large-scale clinical trials, manufacture, marketing and distribution. This strategy allows the company to response quickly to rapid-changing research directions and maintains a modest cost structure.
